Can p38 MAPK Inhibition Mitigate Toxicant-Induced Damage?
Given its central role in stress and inflammatory responses, inhibiting p38 MAPK has been investigated as a strategy to mitigate toxicant-induced damage. Several p38 MAPK inhibitors have been developed, showing promise in preclinical studies by reducing inflammation and cellular damage in response to toxic insults. However, the challenge remains to achieve specific inhibition without affecting the pathway's beneficial roles in normal cellular functions.
